Holen Sie sich die Stockscreener-App
7.24
0.42%
0.03
Handel nachbörslich:
7.27
0.03
+0.41%
Schlusskurs vom Vortag:
$7.21
Offen:
$7.1
24-Stunden-Volumen:
2.15M
Relative Volume:
2.63
Marktkapitalisierung:
$498.18M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-3.978
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+27.46%
1M Leistung:
+9.04%
6M Leistung:
-18.19%
1J Leistung:
-32.65%
1-Tages-Spanne:
$6.8625
$7.58
1-Wochen-Bereich:
$5.57
$7.58
52-Wochen-Spanne:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
7.24 | 390.85M | 46.02M | -70.80M | -1.61M | -1.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st
Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media
Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan
EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada
JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com India
JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com
Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com
EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks
EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail
Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus
Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus
EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus
EyePoint price target lowered to $26 from $30 at Mizuho - TipRanks
Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating - marketscreener.com
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Awards Major Stock Options Package: 7 New Hires Receive 136,700 Shares at $5.72 - Stock Titan
Mizuho cuts EyePoint Pharmaceuticals target to $26 By Investing.com - Investing.com India
Mizuho cuts EyePoint Pharmaceuticals target to $26 - Investing.com
Balyasny Asset Management L.P. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
(EYPT) Technical Data - news.stocktradersdaily.com
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Yahoo Finance
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - MSN
EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks
EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus
Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
EyePoint Pharmaceuticals Q1 2025 Earnings Preview - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):